文献速递临床试验与 GCP真实世界研究与卫生经济

评估埃塞俄比亚数字化依从技术联合差异化关怀支持结核治疗依从性的公平性影响与成本效果:整群随机试验卫生经济学部分的方案与分析计划

Evaluating the equity impact and cost-effectiveness of digital adherence technologies with differentiated care to support tuberculosis treatment adherence in Ethiopia: protocol and analysis plan for the health economics component of a cluster randomised trial.
PubMed 文献 · Trials · 2023-04-24

ASCENT-埃塞俄比亚研究是一项三臂整群随机试验,将78家卫生机构按1:1:1随机分配至两种数字化依从技术(DAT)联合差异化关怀干预组或标准关怀组,评估DAT实施的成本、成本效果与公平性影响。主要效果结局为治疗结束时不利益局(失访、死亡或治疗失败)或治疗结束后6个月内复发的复合指标。成本效果分析将基于终末结局估算避免的伤残调整寿命年(DALY),从每研究臂5家机构、每机构10名参与者(n=150)的亚样本收集提供方与患者成本数据,采用贝叶斯层次模型进行社会成本效果分析,并开展公平性影响分析总结公平-效率权衡。

要点

  • 78家卫生机构按1:1:1随机分为两个DAT干预组和一个标准关怀组,每家机构约纳入50名参与者。
  • 主要效果结局为治疗结束时不利益局(失访、死亡或治疗失败)或治疗结束后6个月内复发的复合指标。
  • 成本效果分析基于终末结局估算避免的DALY,成本数据来自每臂5家机构、每机构10名参与者(n=150)的亚样本。

核心结论

  • 该分析将生成经济证据,为埃塞俄比亚及全球实施DAT提供参考。

研究设计与样本

  • ASCENT-埃塞俄比亚研究为三臂整群随机试验,共78家卫生机构按1:1:1随机分配至两种DAT干预组或标准关怀组。
  • 每家卫生机构约纳入50名参与者,干预组参与者使用与ASCENT依从平台连接的DAT进行每日依从监测并对漏服者采取差异化响应,标准关怀组接受常规照护。
  • 成本数据从每研究臂5家卫生机构、每机构10名参与者(n=150)的亚样本收集提供方与患者成本。
  • 采用贝叶斯层次模型进行社会成本效果分析,模型考虑成本与结局的个体水平相关性及整群内相关性。

主要发现

  • 主要效果结局为治疗结束时不利益局(失访、死亡或治疗失败)或治疗结束后6个月内复发的复合指标。
  • 成本效果分析将使用终末结局估算避免的DALY。
  • 将开展公平性影响分析以总结公平-效率权衡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis remains a leading infectious cause of death in resource-limited settings. Effective treatment is the cornerstone of tuberculosis control, reducing mortality, recurrence and transmission. Supporting treatment adherence through facility-based observations of medication taking can be costly to providers and patients. Digital adherence technologies (DATs) may facilitate treatment monitoring and differentiated care. The ASCENT-Ethiopia study is a three-arm cluster randomised trial assessing two DATs with differentiated care for supporting tuberculosis treatment adherence in Ethiopia. This study is part of the ASCENT consortium, assessing DATs in South Africa, the Philippines, Ukraine, Tanzania and Ethiopia. The aim of this study is to determine the costs, cost-effectiveness and equity impact of implementing DATs in Ethiopia. METHODS AND DESIGN: A total of 78 health facilities have been randomised (1:1:1) into one of two intervention arms or a standard-of-care arm. Approximately 50 participants from each health facility will be enrolled on the trial. Participants in facilities randomised to the intervention arms are offered a DAT linked to the ASCENT adherence platform for daily adherence monitoring and differentiated response for those who have missed doses. Participants at standard-of-care facilities receive routine care. Treatment outcomes and resource utilisation will be measured for each participant. The primary effectiveness outcome is a composite index of unfavourable end-of-treatment outcomes (lost to follow-up, death or treatment failure) or treatment recurrence within 6 months of end-of-treatment. For the cost-effectiveness analysis, end-of-treatment outcomes will be used to estimate disability-adjusted life years (DALYs) averted. Provider and patient cost data will be collected from a subsample of 5 health facilities per study arm, 10 participants per facility (n = 150). We will conduct a societal cost-effectiveness analysis using Bayesian hierarchical models that account for the individual-level correlation between costs and outcomes as well as intra-cluster correlation. An equity impact analysis will be conducted to summarise equity efficiency trade-offs. DISCUSSION: Trial enrolment is ongoing. This paper follows the published trial protocol and describes the protocol and analysis plan for the health economics work package of the ASCENT-Ethiopia trial. This analysis will generate economic evidence to inform the implementation of DATs in Ethiopia and globally. TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR) PACTR202008776694999. Registered on 11 August 2020, https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12241 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Foster N, Tadesse AW, McQuaid CF, et al. Evaluating the equity impact and cost-effectiveness of digital adherence technologies with differentiated care to support tuberculosis treatment adherence in Ethiopia: protocol and analysis plan for the health economics component of a cluster randomised trial. Trials. 2023. PMID: 37095533. doi:10.1186/s13063-023-07289-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。